Pharmaceuticals News

NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- LifeSci Partners, a life science focused consultancy, announced today the launch of LifeSci Events, which supports life sciences companies with turnkey...

Provides Details on Current Board’s Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution Company Commits to Distributing $45 Million to Stockholders in an...

Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision...

CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...

Submission has been granted priority review and given a target regulatory decision date of November 30, 2022.If approved for this second indication, BREXAFEMME would be the first and only therapy...

CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...

Gary Nabel, MD, PhD, Chief Innovation Officer of OPKO and Chief Executive Officer, ModeX Therapeutics, Inc., an OPKO Health companyJoseph Papa, Chief Executive Officer of Bausch + Lomb...

WATERTOWN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...

-Common stock of Apexigen to commence trading on the Nasdaq Capital Market today under the ticker symbol “APGN”- -Clinical pipeline includes multiple Phase 2 studies of sotigalimab, a CD40 agonist...

SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...